Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
Hainsworth, John D., Becker, Kevin P., Mekhail, Tarek, Chowdhary, Sajeel A., Eakle, Janice Faulkner, Wright, David, Langdon, Robert M., Yost, Kathleen J., Padula, Gilbert Darin Anthony, West-Osterfield, Kimberly, Scarberry, Meredith, Shaifer, Candice A., Shastry, Mythili, Burris, Howard A., Shih, Kent
Published in Journal of neuro-oncology (01.09.2019)
Published in Journal of neuro-oncology (01.09.2019)
Get full text
Journal Article